
A RSV vaccine candidate for newborns, which was developed in a collaboration between Boston Children’s Hospital and researchers from the Danish State Serum Institute, SSI, has reported promising results after testing with mice, the Danish vaccine authority writes in a press release.
Following the successful study, preparations for human testing have begun.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app